Transdermal delivery of dopaminergic agentsRASCOL, Olivier.Neurology. 2005, Vol 65, Num 2, issn 0028-3878, 16 p., SUP1Serial Issue

A novel dopamine agonist for the transdermal treatment of Parkinson's diseaseJENNER, Peter.Neurology. 2005, Vol 65, Num 2, pp S3-S5, issn 0028-3878, SUP1Article

Dyskinesia: L-dopa-induced and tardive dyskinesiaRASCOL, Olivier; FABRE, Nelly.Clinical neuropharmacology. 2001, Vol 24, Num 6, pp 313-323, issn 0362-5664Article

A promising new technology for Parkinson's diseasePFEIFFER, Ronald F.Neurology. 2005, Vol 65, Num 2, pp S6-S10, issn 0028-3878, SUP1Article

Dopamine Receptor Agonists for the Treatment of Early or Advanced Parkinson's DiseasePEREZ-LLORET, Santiago; RASCOL, Olivier.CNS drugs. 2010, Vol 24, Num 11, pp 941-968, issn 1172-7047, 28 p.Article

Les agonistes dopaminergiques = Dopamine agonistsORY-MAGNE, Fabienne; BREFEL-COURBON, Christine; RASCOL, Olivier et al.Neurologie.com. 2009, Vol 1, Num 5, pp 145-148, issn 2100-9511, 4 p.Article

Milestones in Parkinson's Disease TherapeuticsRASCOL, Olivier; LOZANO, Andres; STERN, Matthew et al.Movement disorders. 2011, Vol 26, Num 6, pp 1072-1082, issn 0885-3185, 11 p.Article

Disease-modification trials in Parkinson disease : Target populations, endpoints and study designRASCOL, Olivier.Neurology. 2009, Vol 72, Num 7, issn 0028-3878, S51-S58, SUP2Article

Clinical studies with transdermal rotigotine in early Parkinson's diseasePOEWE, W; LEUSSI, F.Neurology. 2005, Vol 65, Num 2, pp S11-S14, issn 0028-3878, SUP1Article

Recherche clinique, innovations et hôpital. DossierBONHOMME, Catherine; DEVILLIERS, Elisabeth; RASCOL, Olivier et al.Revue hospitalière de France (Paris). 2011, Num 543, pp 12-25, issn 0397-4626, 14 p.Article

Investissements d'avenir. Le projet F-CRIN (French Clinical Research Infrastructure Network)RASCOL, Olivier; IFRAH, Norbert; LEVY-MARCHAL, Claire et al.Revue hospitalière de France (Paris). 2011, Num 543, pp 16-17, issn 0397-4626, 2 p.Article

CONTROLE CENTRAL ET REGULATION DE LA PRESSION SANGUINE ARTERIELLE PAR LES SYSTEMES CHOLINERGIQUES CENTRAUX. APPROCHE PHARMACOLOGIQUE = BLOOD PRESSURE REGULATION AND CONTROL BY CENTRAL CHOLINERGIC SYSTEMS. PHARMACOLOGICAL APPROACHLazartigues, Eric; Rascol, Olivier.1999, 257 p.Thesis

Les mécanismes cholinergiques dans la voie septohippocampique chez le rat: Approches électrophysiologique et pharmacologique = Cholinergic mechanisms in the rat septohippocampal patway: An electrophysiological and pharmacological studyRascol, Olivier; Montastruc, Jean-Louis.1992, 365 p.Thesis

Efficacy of Piribedil as early combination to levodopa in patients with stable Parkinson's disease: A 6-month, randomized, placebo-controlled studyZIEGLER, Marc; CASTRO-CALDAS, Alexandre; DEL SIGNORE, Susanna et al.Movement disorders. 2003, Vol 18, Num 4, pp 418-425, issn 0885-3185, 8 p.Article

Continuous dopamine-receptor stimulation in early Parkinson's diseaseOLANOW, C. Warren; SCHAPIRA, Anthony H. V; RASCOL, Olivier et al.Trends in neurosciences (Regular edition). 2000, Vol 23, Num 10, pp S117-S126, issn 0166-2236, SUPArticle

Treatment interventions for Parkinson's disease: an evidence based assessmentRASCOL, Olivier; GOETZ, Christopher; KOLLER, William et al.Lancet (British edition). 2002, Vol 359, Num 9317, pp 1589-1598, issn 0140-6736Article

Evidence-based medical review update : Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004GOETZ, Christopher G; POEWE, Werner; RASCOL, Olivier et al.Movement disorders. 2005, Vol 20, Num 5, pp 523-539, issn 0885-3185, 17 p.Article

Hereditary ferritinopathyVIDAL, Ruben; DELISLE, Marie Bernadette; RASCOL, Olivier et al.Journal of the neurological sciences. 2003, Vol 207, Num 1-2, pp 110-111, issn 0022-510X, 2 p.Conference Paper

Selective serotonin reuptake inhibitor paroxetine modulates motor behavior through practice. A double-blind, placebo-controlled, multi-dose study in healthy subjectsLOUBINOUX, Isabelle; PARIENTE, Jérémie; RASCOL, Olivier et al.Neuropsychologia. 2002, Vol 40, Num 11, pp 1815-1821, issn 0028-3932Article

Adverse Drug Reactions to Dopamine Agonists: A Comparative Study in the French Pharmacovigilance DatabasePEREZ-LLORET, Santiago; BONDON-GUITTON, Emmanuelle; RASCOL, Olivier et al.Movement disorders. 2010, Vol 25, Num 12, pp 1876-1880, issn 0885-3185, 5 p.Article

Orthostatic hypotension in patients with Parkinson's disease : Pathophysiology and managementSENARD, Jean-Michel; BREFEL-COURBON, Christine; RASCOL, Olivier et al.Drugs & aging. 2001, Vol 18, Num 7, pp 495-505, issn 1170-229XArticle

Rotigotine transdermal patch for the treatment of Parkinson's DiseasePEREZ-LLORET, Santiago; VERONICA REY, Maria; RATTI, Pietro Lucca et al.Fundamental & clinical pharmacology. 2013, Vol 27, Num 1, pp 81-95, issn 0767-3981, 15 p.Article

Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: Pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over studyZIJLMANS, Jan C. M; DEBILLY, Berengere; RASCOL, Olivier et al.Movement disorders. 2004, Vol 19, Num 9, pp 1006-1011, issn 0885-3185, 6 p.Article

Withdrawing amantadine in dyskinetic patients with Parkinson disease: The AMANDYSK trialORY-MAGNE, Fabienne; CORVOL, Jean-Christophe; LEBOUVIER, Thibaud et al.Neurology. 2014, Vol 82, Num 4, pp 300-307, issn 0028-3878, 8 p.Article

The Unified Multiple System Atrophy Rating Scale: Intrarater ReliabilityKRISMER, Florian; SEPPI, Klaus; BOZI, Maria et al.Movement disorders. 2012, Vol 27, Num 13, pp 1683-1685, issn 0885-3185, 3 p.Article